![Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet](https://www.thelancet.com/cms/asset/aee99cbc-80a0-49e4-9ac3-6cc4f16265f9/gr1.jpg)
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet
![Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study - The Lancet Oncology Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study - The Lancet Oncology](https://www.thelancet.com/cms/asset/68d4b7e3-b891-4491-9ab0-cbba4b4030a2/gr1.jpg)
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study - The Lancet Oncology
![The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance - ScienceDirect The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0048969722028649-ga1.jpg)
The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance - ScienceDirect
![Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial - The Lancet Oncology Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/f0a7ba64-a0fc-4e7f-8966-c1723493d832/gr1.jpg)
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial - The Lancet Oncology
![Alfa Romeo Stelvio - The Italian Brand's first SUV in over a century of history | Alfa Romeo | Stellantis Alfa Romeo Stelvio - The Italian Brand's first SUV in over a century of history | Alfa Romeo | Stellantis](https://www.media.stellantis.com/cache/3/b/c/5/a/3bc5a8882279d97d626a91d5839e2d6ec80d18f7.jpeg)
Alfa Romeo Stelvio - The Italian Brand's first SUV in over a century of history | Alfa Romeo | Stellantis
![City Sightseeing Italy: more than 100 red scenic buses, excursions, tours and tickets skip the line in 14 tourist destinations. City Sightseeing Italy: more than 100 red scenic buses, excursions, tours and tickets skip the line in 14 tourist destinations.](https://cdn.city-sightseeing.it/Destination/9/3a78cf53-37eb-4c22-8992-0258941d7cdf.jpg)
City Sightseeing Italy: more than 100 red scenic buses, excursions, tours and tickets skip the line in 14 tourist destinations.
![Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - The Lancet Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/d21b0488-8d13-4c75-86eb-0bb2a98f8b88/gr1.jpg)
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - The Lancet
![FRONTLINE Combo, 1 Pipetta, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci, Zecche, Uova, Larve e Anche la Casa, Antipulci In Confezione da 1 Pipetta da 0.5 ml : FRONTLINE Combo, 1 Pipetta, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci, Zecche, Uova, Larve e Anche la Casa, Antipulci In Confezione da 1 Pipetta da 0.5 ml :](https://m.media-amazon.com/images/I/81QEZ9XrquL._AC_UF1000,1000_QL80_.jpg)
FRONTLINE Combo, 1 Pipetta, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci, Zecche, Uova, Larve e Anche la Casa, Antipulci In Confezione da 1 Pipetta da 0.5 ml :
![FRONTLINE Combo, 1 Pipetta, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci, FRONTLINE Combo, 1 Pipetta, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci,](https://m.media-amazon.com/images/I/81YUj41-gSL._AC_UF1000,1000_QL80_.jpg)